Latest Breaking News On - Vu university - Page 14 : comparemela.com

19 Dec 2020 The anti-inflammatory medication masitinib met its primary endpoint in an Alzheimer’s disease trial, according to topline data announced December 16 by its sponsor, the Paris-based company AB Science. In the six-month Phase 2b/3 study of 718 AD patients, the drug appeared to halt cognitive decline, with the treatment group, on average, notching slight improvements on the ADAS-Cog. In addition, fewer patients on drug than placebo progressed to severe dementia. The trial, which started seven years ago, did not include any biomarker data. Masitinib maintained cognition and function in people with mild to moderate AD. The drug is believed to dampen inflammation via microglia and mast cells.

France generalUniversity of southern californiaUnited statesSan diegoNoord hollandComunidad autonoma de catalunaMadolyn bowman rogersPaul aisenPhilip scheltensAlain moussyElena galeaJeroen hoozemans at amsterdam university medical centerVu universityTv therapeutics incUniversitat autSouthern california